Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis.

Sun J, Hua B, Livingston EW, Taves S, Johansen PB, Hoffman M, Ezban M, Monroe DM, Bateman TA, Monahan PE.

Blood. 2017 Apr 13;129(15):2161-2171. doi: 10.1182/blood-2016-08-734053. Epub 2016 Dec 30.

2.

Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.

Sun J, Hakobyan N, Valentino LA, Feldman BL, Samulski RJ, Monahan PE.

Blood. 2008 Dec 1;112(12):4532-41. doi: 10.1182/blood-2008-01-131417. Epub 2008 Aug 20.

3.

Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B.

McDonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM.

J Thromb Haemost. 2007 Aug;5(8):1577-83.

4.

An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model.

Hoffman M, Chang JY, Ezban M, Monroe DM.

J Thromb Haemost. 2016 Jun;14(6):1249-54. doi: 10.1111/jth.13311. Epub 2016 Apr 5.

5.

Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.

Monahan PE, Sun J, Gui T, Hu G, Hannah WB, Wichlan DG, Wu Z, Grieger JC, Li C, Suwanmanee T, Stafford DW, Booth CJ, Samulski JJ, Kafri T, McPhee SW, Samulski RJ.

Hum Gene Ther. 2015 Feb;26(2):69-81. doi: 10.1089/hum.2014.106. Epub 2015 Jan 21.

6.

Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.

Perot E, Enjolras N, Le Quellec S, Indalecio A, Girard J, Negrier C, Dargaud Y.

Thromb Res. 2015 May;135(5):1017-24. doi: 10.1016/j.thromres.2015.02.034. Epub 2015 Mar 10.

PMID:
25795563
7.

Progressive improvement in wound healing with increased therapy in haemophilia B mice.

Monroe DM, Hoffman M, Roberts HR, Hedner U.

Haemophilia. 2013 Nov;19(6):926-32. doi: 10.1111/hae.12220. Epub 2013 Jul 23.

PMID:
23879625
8.

Novel, high incidence exercise-induced muscle bleeding model in hemophilia B mice: rationale, development and prophylactic intervention.

Tranholm M, Kristensen AT, Broberg ML, Groth MP.

J Thromb Haemost. 2015 Jan;13(1):82-91. doi: 10.1111/jth.12775. Epub 2014 Dec 11.

9.

Cutaneous wound healing is impaired in hemophilia B.

Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM.

Blood. 2006 Nov 1;108(9):3053-60. Epub 2006 Jul 6.

10.

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.

Toby GG, Liu T, Buyue Y, Zhang X, Bitonti AJ, Pierce GF, Sommer JM, Jiang H, Peters RT.

PLoS One. 2016 Feb 3;11(2):e0148255. doi: 10.1371/journal.pone.0148255. eCollection 2016.

11.

The clotting system - a major player in wound healing.

Monroe DM, Hoffman M.

Haemophilia. 2012 Jul;18 Suppl 5:11-6. doi: 10.1111/j.1365-2516.2012.02889.x.

PMID:
22757679
12.

Wound healing in hemophilia B mice and low tissue factor mice.

Monroe DM, Mackman N, Hoffman M.

Thromb Res. 2010 Apr;125 Suppl 1:S74-7. doi: 10.1016/j.thromres.2010.01.043. Epub 2010 Feb 19. Review.

13.

Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity.

Hoffman M, Monroe DM.

Wound Repair Regen. 2012 Sep-Oct;20(5):770-7. doi: 10.1111/j.1524-475X.2012.00828.x. Epub 2012 Aug 10.

PMID:
22882528
14.

Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.

Østergaard H, Bjelke JR, Hansen L, Petersen LC, Pedersen AA, Elm T, Møller F, Hermit MB, Holm PK, Krogh TN, Petersen JM, Ezban M, Sørensen BB, Andersen MD, Agersø H, Ahmadian H, Balling KW, Christiansen ML, Knobe K, Nichols TC, Bjørn SE, Tranholm M.

Blood. 2011 Aug 25;118(8):2333-41. doi: 10.1182/blood-2011-02-336172. Epub 2011 Jun 23.

15.

Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.

Nummi V, Jouppila A, Lassila R.

Int J Lab Hematol. 2017 Aug;39(4):359-368. doi: 10.1111/ijlh.12634. Epub 2017 Apr 13.

PMID:
28406575
16.

In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.

Enjolras N, Perot E, Le Quellec S, Indalecio A, Girard J, Negrier C, Dargaud Y.

Haemophilia. 2015 Jul;21(4):e317-21. doi: 10.1111/hae.12688. Epub 2015 May 15.

PMID:
25981983
17.

Prolonged activity of factor IX as a monomeric Fc fusion protein.

Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q, Zarbis-Papastoitsis G, Reidy TJ, Merricks EP, Nichols TC, Bitonti AJ.

Blood. 2010 Mar 11;115(10):2057-64. doi: 10.1182/blood-2009-08-239665. Epub 2010 Jan 7.

18.

Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.

Lin CN, Kao CY, Miao CH, Hamaguchi N, Wu HL, Shi GY, Liu YL, High KA, Lin SW.

J Thromb Haemost. 2010 Aug;8(8):1773-83. doi: 10.1111/j.1538-7836.2010.03913.x. Epub 2010 May 21.

19.

Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.

Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC Jr, Garzone PD, Schaub RG.

Blood. 1996 Oct 1;88(7):2603-10.

20.

Supplemental Content

Support Center